Biogen Announces FDA Approves High Dose Regimen of SPINRAZA To Treat Spinal Muscular Atrophy

Biogen Inc. announced that the FDA has approved a High Dose Regimen of SPINRAZA (nusinersen) for treating spinal muscular atrophy (SMA). This new regimen includes 50 mg and 28 mg doses, designed to provide a higher concentration of the drug during both loading and maintenance phases. The High Dose SPINRAZA will allow for an accelerated loading phase for new patients and will be available in the coming weeks.